TAILIEUCHUNG - MALIGNANT MESOTHELIOMA

This book brings together the knowledge of eminent experts in the field of malignant mesothelioma, a highly invasive tumor of mesothelium that is the protective lining covering several body cavities. Malignant mesothelioma shows extremely poor progression and is refractory to almost any kind of therapy putting considerable challenges in its treatment. This book covers many important aspects of malignant mesothelioma like epidemiology, immunology, molecular mechanisms and clinical options and will be useful to anybody interested in its history, pathology, and treatment | MALIGNANT MESOTHELIOMA Edited by Carmen Belli and Santosh Anand Malignant Mesothelioma http 1648 Edited by Carmen Belli and Santosh Anand Contributors James I. Phillips David Rees Jill Murray John . Davies Yasumitsu Nishimura Megumi Maeda Naoko Kumagai-Takei Hidenori Matsuzaki Suni Lee Kazuya Fukuoka Takashi Nakano Takumi Kishimoto Takemi Otsuki Loredana Albonici Camilla Palumbo Vittorio Manzari Rossella Galati Giulia Pasello Adolfo Favaretto Published by InTech Janeza Trdine 9 51000 Rijeka Croatia Copyright 2012 InTech All chapters are Open Access distributed under the Creative Commons Attribution license which allows users to download copy and build upon published articles even for commercial purposes as long as the author and publisher are properly credited which ensures maximum dissemination and a wider impact of our publications. After this work has been published by InTech authors have the right to republish it in whole or part in any publication of which they are the author and to make other personal use of the work. Any republication referencing or personal use of the work must explicitly identify the original source. Notice Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the use of any materials instructions methods or ideas contained in the book. Publishing Process Manager Sandra Bakic Typesetting InTech Prepress Novi Sad Cover InTech Design Team First published December 2012 Printed in Croatia A free online edition of this book is available at Additional hard copies can be obtained from orders@ Malignant Mesothelioma Edited by Carmen Belli and Santosh Anand p. cm. ISBN 978-953-51-0901-3

• Y học thường thức
• Malignant Mesothelioma
• Pleural Mesothelioma
• Angiogenic Growth Factors
• Neoadjuvant Chemotherapy
• immunology
• molecular mechanisms
• BMC Cancer
• Overall survival
• Malignant pleural mesothelioma
• Therapy response
• Chemotherapeutic treatment
• Tumor marker
• Malignant tumor
• Mesothelial origin
• Conventional chemotherapy
• Mesothelioma diagnostic imaging
• Mesothelioma drug therapy
• Magnetic resonance imaging
• Progression free survival
• Diagnostic marker
• Enzyme linked immunosorbent assays
• Area under the curve
• MPM diagnosis remains
• Functional measures
• Surgical approach
• Quality of life
• Extrapleural pneumonectomy
• Debilitating disease
• Pleural cavity
• Asbestos fibers
• Patient centered care
• Physician requests
• Patient physician communication
• Tumor stroma
• Asbestos exposure
• Fluorescence in situ hybridization
• Exome sequencing
• Mouse model
• Wild type
• Human counterpart
• Palliative care
• Asbestos related diseases
• Tumor regression
• Malignant epithelioid mesothelioma
• Standard chemotherapy
• Systemic chemotherapy
• Septin 7
• Transcriptional regulation
• Calcium binding protein calretinin
• Butyrate responsive elements
• PD 1 antibody
• Minimal change disease
• Interstitial nephritis
• Lung cancer
• Modelling and simulation
• Computational oncology
• Toxicity balance
• Poor prognosis
• Chemotherapy regimens
• Yielded disease
• Carboplatin plus gemcitabine
• Systemic treatment
• Platinum–based chemotherapy
• Targeted therapy
• Preclinical models
• Reactive oxygen species
• Translational oncology
• Cancer stem cells
• Patient survival
• Aldehyde dehydrogenase
• Prognostic indicator
• Routine clinical practice
• Pleural effusions
• Primary cells
• Ex vivo chemosensitivity
• Cytotoxic drugs
• Individualized treatment
• Proteasome inhibitor
• Epidermal growth factor receptor
• PI3K/Akt signaling
• Industrialized countries
• MPM incidence
• Chimeric antigen receptor
• Cancer treatment
• Malignant peritoneal mesothelioma
• Second line chemotherapy
• Standard treatment
• Multivariate analyses
• Inflammatory cancer
• Emerging avenues
• Checkpoint inhibitors
• Non small cell lung cancer